Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes.

Hdl Handle:
http://hdl.handle.net/10147/126465
Title:
Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes.
Authors:
O'Sullivan, Eoin P; Ashley, David T; Davenport, Colin; Devlin, Niamh; Crowley, Rachel; Agha, Amar; Thompson, Christopher J; O'Gorman, Donal; Smith, Diarmuid
Affiliation:
Department of Diabetes, Royal College of Surgeons in Ireland Medical School, Beaumont Hospital, Dublin, Ireland.
Citation:
Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes. 2010, 26 (6):496-502 Diabetes Metab. Res. Rev.
Journal:
Diabetes/metabolism research and reviews
Issue Date:
Sep-2010
URI:
http://hdl.handle.net/10147/126465
DOI:
10.1002/dmrr.1109
PubMed ID:
20809534
Abstract:
Osteoprotegerin (OPG), receptor activator for nuclear factor kappa beta ligand (RANKL) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) are newly discovered members of the tumour necrosis factor-alpha receptor superfamily. While their role in bone metabolism is well described, their function within the vasculature is poorly understood. OPG inhibits vascular calcification in vitro and high serum levels have been demonstrated in type 2 diabetes, but serum RANKL and TRAIL and their potential correlation with well-established biomarkers of subclinical vascular inflammation such as high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) have not been described.; Sixty-two patients with well-controlled type 2 diabetes and an age, gender and body mass index-matched group of 58 healthy individuals were recruited. Serum OPG, RANKL and TRAIL were measured using commercial enzyme-linked immunosorbent assays, as were hsCRP and IL-6.; Serum OPG, IL-6 and hsCRP levels, but not RANKL or TRAIL, were higher in patients with type 2 diabetes mellitus than in healthy controls, after adjustment for age and gender. After exclusion of diabetes patients with a history of micro- or macrovascular disease, OPG remained significantly higher in those with diabetes, but IL-6 and hsCRP levels were no longer elevated. There was a positive correlation between OPG and IL-6 in the group as a whole, but no correlation was found between RANKL or TRAIL and either hsCRP or IL-6.; OPG, but not RANKL or TRAIL, is significantly increased in type 2 diabetes. Higher OPG (but not IL-6 or hsCRP) in those without vascular disease suggests these biomarkers reflect separate pathophysiological processes in the vasculature.
Item Type:
Article
Language:
en
MeSH:
Biological Markers; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Inflammation; Interleukin-6; Male; Middle Aged; Osteoprotegerin; RANK Ligand; TNF-Related Apoptosis-Inducing Ligand
ISSN:
1520-7560

Full metadata record

DC FieldValue Language
dc.contributor.authorO'Sullivan, Eoin Pen
dc.contributor.authorAshley, David Ten
dc.contributor.authorDavenport, Colinen
dc.contributor.authorDevlin, Niamhen
dc.contributor.authorCrowley, Rachelen
dc.contributor.authorAgha, Amaren
dc.contributor.authorThompson, Christopher Jen
dc.contributor.authorO'Gorman, Donalen
dc.contributor.authorSmith, Diarmuiden
dc.date.accessioned2011-03-31T08:03:11Z-
dc.date.available2011-03-31T08:03:11Z-
dc.date.issued2010-09-
dc.identifier.citationOsteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes. 2010, 26 (6):496-502 Diabetes Metab. Res. Rev.en
dc.identifier.issn1520-7560-
dc.identifier.pmid20809534-
dc.identifier.doi10.1002/dmrr.1109-
dc.identifier.urihttp://hdl.handle.net/10147/126465-
dc.description.abstractOsteoprotegerin (OPG), receptor activator for nuclear factor kappa beta ligand (RANKL) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) are newly discovered members of the tumour necrosis factor-alpha receptor superfamily. While their role in bone metabolism is well described, their function within the vasculature is poorly understood. OPG inhibits vascular calcification in vitro and high serum levels have been demonstrated in type 2 diabetes, but serum RANKL and TRAIL and their potential correlation with well-established biomarkers of subclinical vascular inflammation such as high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) have not been described.-
dc.description.abstractSixty-two patients with well-controlled type 2 diabetes and an age, gender and body mass index-matched group of 58 healthy individuals were recruited. Serum OPG, RANKL and TRAIL were measured using commercial enzyme-linked immunosorbent assays, as were hsCRP and IL-6.-
dc.description.abstractSerum OPG, IL-6 and hsCRP levels, but not RANKL or TRAIL, were higher in patients with type 2 diabetes mellitus than in healthy controls, after adjustment for age and gender. After exclusion of diabetes patients with a history of micro- or macrovascular disease, OPG remained significantly higher in those with diabetes, but IL-6 and hsCRP levels were no longer elevated. There was a positive correlation between OPG and IL-6 in the group as a whole, but no correlation was found between RANKL or TRAIL and either hsCRP or IL-6.-
dc.description.abstractOPG, but not RANKL or TRAIL, is significantly increased in type 2 diabetes. Higher OPG (but not IL-6 or hsCRP) in those without vascular disease suggests these biomarkers reflect separate pathophysiological processes in the vasculature.-
dc.language.isoenen
dc.subject.meshBiological Markers-
dc.subject.meshC-Reactive Protein-
dc.subject.meshDiabetes Mellitus, Type 2-
dc.subject.meshDiabetic Angiopathies-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInflammation-
dc.subject.meshInterleukin-6-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshOsteoprotegerin-
dc.subject.meshRANK Ligand-
dc.subject.meshTNF-Related Apoptosis-Inducing Ligand-
dc.titleOsteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes.en
dc.typeArticleen
dc.contributor.departmentDepartment of Diabetes, Royal College of Surgeons in Ireland Medical School, Beaumont Hospital, Dublin, Ireland.en
dc.identifier.journalDiabetes/metabolism research and reviewsen
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.